Depo Provera® [Medroxyprogesterone]
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Depo Provera® is an anticancer drug, the gestagen is a depot form. Does not possess androgenic and estrogenic activity. Depo-Provera inhibits the secretion of gonadotropic hormones (especially LH). In small doses, inhibits ovulation. It has an inhibitory effect on the changes needed to prepare the endometrium for implantation of a fertilized egg and increases the viscosity of the mucus of the cervix. Depo-Provera in higher doses has an antitumor effect in hormone-sensitive malignant tumors. This effect is apparently due to the action on steroid hormone receptors and on the pituitary-gonadal system.
Additional and palliative treatment for recurrent and metastatic endometrial cancer or kidney cancer; palliative treatment for hormone-dependent forms of recurrent breast cancer in postmenopausal women.
1 ml of suspension contains:
Active substance: methylprednisolone acetate 150 mg;
Excipients: polyethylene glycol 3350; polysorbate 80; sodium chloride; methyl paraben; propyl paraben; water for injections.
No customer reviews for the moment.
Dosage and Administration
Set individually, depending on the evidence, the stage of the disease, the treatment regimen.
Withendometrial cancer and kidney cancer the initial dose is 400-1000 mg per week IM. If within a few weeks or months there has been an improvement and stabilization of the process has been achieved, then maintenance therapy is prescribed at a dose of 400 mg per month.
In breast cancer the drug is administered i / m at the initial dose of 500 mg per day for 28 days. Then use maintenance doses - 500 mg 2 times a week. Treatment continues until signs of disease progression.
Immediately before use, the vial should be shaken well, so that the injected drug takes on the appearance of a homogeneous suspension.
Allergic reactions:anaphylaxis and anaphylactoid reactions, urticaria.
From the blood coagulation system: thromboembolism, thrombophlebitis.
From the side of the central nervous system: increased nervous irritability, insomnia, drowsiness, fatigue, depression, dizziness, headache.
Dermatological reactions: itching, rash, acne, hirsutism and alopecia.
From the reproductive system: dysfunctional uterine bleeding, bloody discharge from the genital tract, amenorrhea, decreased libido or anorgasmia, vaginitis, leucorrhea, hot flashes, lower abdominal pain, breast tenderness, galactorrhea.
From the digestive system: pain or discomfort in the stomach, nausea, flatulence.
From the musculoskeletal system: cramps gastrocnemius muscles, pain in the back and joints.
Other: asthenia, hyperthermia, change in body weight and moon face.
Hypersensitivity to the components of the drug, pregnancy, lactation.
It is necessary to strictly observe the compliance of the used dosage form of the drug with indications for use.
Medroxyprogesterone should be used with extreme caution in patients with thrombophlebitis, thromboembolic complications, severe impaired liver function, and hypercalcemia.
Before using medroxyprogesterone for the treatment of gynecological diseases and contraception it is necessary to exclude the presence in the patient of a tumor of the genital organs or mammary glands.
When conducting histopathological studies of certain organs and tissues, it is necessary to warn the histologist about the previous treatment with progestogens. Against the background of medroxyprogesterone, changes in the results of the following studies are possible: determination of the level of gonadotropins; determining the level of progesterone, cortisol, testosterone (in men), estrogen (in women) in the blood plasma; determination of the level of pregnandiol in the urine; carrying out tests with sugar loading; a test with a metapiron.
- Brand name: Delagil
- Active ingredient: Chloroquine
- Dosage form: pills
- Manufacturer: Meda Pharma GmbH & Co. KG
- Country of Origin: Switzerland
- Cholelithiasis induced in the Syrian hamster: Evidence for an intramucinous nucleating process and down regulation of cholesterol 7α-hydroxylase (CYP7) gene by medroxyprogesterone
- Effects of medroxyprogesterone acetate on food intake, body composition, and resting energy expenditure in patients with advanced, nonhormone-sensitive cancer : A randomized, placebo-controlled trial
- Cytologic changes in cervical smears associated with prolonged use of depot-medroxyprogesterone acetate
- Short term pretreatment with medroxyprogesterone and testosterone may potentiate irradiation damage to spermatogenesis in rats
- Medroxyprogesterone acetate inhibits human pancreatic carcinoma cell growth by inducing apoptosis in association with Bcl-2 phosphorylation
- Inhibitory effect of the novel anti-estrogen EM-800 and medroxyprogesterone acetate on estrone-stimulated growth of dimethylbenz[a]anthracene-induced mammary carcinoma in rats
- Pharmacokinetics of 9α-fluoromedroxyprogesterone acetate in rats: comparison with medroxyprogesterone acetate
- Hormonal therapy in cancer of the breast. XXIV. Effect of corticosterone or medroxyprogesterone acetate on clinical course and hormonal excretion
- Medroxyprogesterone acetate in the treatment of renal cell carcinoma (hypernephroma)
- Radiosensitization of endometrial adenocarcinoma by means of medroxyprogesterone
- Combination chemotherapy of germ cell tumors of the testis with vincristine, adriamycin, cyclophosphamide, actinomycin D and medroxyprogesterone acetate
- Medroxyprogesterone acetate (depo-provera) vs. hydroxyprogesterone caproate (Delalutin) in women with metastatic endometrial adenocarcinoma
- Pharmacokinetic and pharmacodynamic basis for the treatment of metastatic breast cancer with high-dose medroxyprogesterone acetate
- Radiosensitizing effect of medroxyprogesterone acetate on endometrial cancer cells in vitro
- Fatal pulmonary toxicity by the association of radiotherapy and medroxyprogesterone acetate
- A phase III trial of oral high-dose medroxyprogesterone acetate (MPA) versus mepitiostane in advanced postmenopausal breast cancer
- Oral high-dose medroxyprogesterone acetate versus tamoxifen: A randomized crossover trial in postmenopausal patients with advanced breast cancer
- Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer: A phase II study of the association of medical oncology of the German cancer society (AIO)
- Clinical trial of high-dose oral medroxyprogesterone acetate in the treatment of metastatic breast cancer and review of the literature
- High-dose medroxyprogesterone acetate in advanced breast cancer. Clinical and pharmacokinetic study with a combined oral and intramuscular regimen
- Inability of medroxyprogesterone acetate to down regulate estrogen receptor level in human breast cancer
- Medroxyprogesterone acetate lowers plasma corticotropin and cortisol but does not suppress anterior pituitary responsiveness to human corticotropin releasing factor
- Sequentially administered ethinyl estradiol and medroxyprogesterone acetate in the treatment of refractory epithelial ovarian carcinoma in patients with positive estrogen receptors
- Failure of down-regulation of estrogen receptors and progesterone receptors after medroxyprogesterone acetate administration for endometrial hyperplasias